Literature DB >> 20727564

Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment.

Christopher S Davis1, Vidya Shankaran, Elizabeth J Kovacs, James Gagermeier, Daniel Dilling, Charles G Alex, Robert B Love, James Sinacore, P Marco Fisichella.   

Abstract

BACKGROUND: Gastroesophageal reflux disease (GERD) is thought to be a risk factor for the development or progression of chronic rejection after lung transplantation. However, the prevalence of GERD and its risk factors, including esophageal dysmotility, hiatal hernia and delayed gastric emptying after lung transplantation, are still unknown. In addition, the prevalence of Barrett's esophagus, a known complication of GERD, has not been determined in these patients. The purpose of this study was to determine the prevalence and extent of GERD, as well as the frequency of these risk factors and complications of GERD in lung transplant patients.
METHODS: Thirty-five consecutive patients underwent a combination of esophageal function testing, upper endoscopy, barium swallow, and gastric emptying scan after lung transplantation.
RESULTS: In this patient population, the prevalence of GERD was 51% and 22% in those who had been retransplanted. Of patients with GERD,36% had ineffective esophageal motility (IEM), compared with 6% of patients without GERD (P = .037). No patient demonstrated hiatal hernia on barium swallow. The prevalence of delayed gastric emptying was 36%. The prevalence of biopsy-confirmed Barrett's esophagus was 12%.
CONCLUSION: Our study shows that, after lung transplantation, more than half of patients had GERD, and that GERD was more common after retransplantation. IEM and delayed gastric emptying are frequent in patients with GERD. Hiatal hernia is rare. The prevalence of Barrett's esophagus is not negligible. We conclude that GERD is highly prevalent after lung transplantation, and that delayed gastric emptying and Barrett's esophagus should always be suspected after lung transplantation because they are common risks factors and complications of GERD.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20727564      PMCID: PMC3066258          DOI: 10.1016/j.surg.2010.07.011

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

Review 1.  Bronchiolitis obliterans after human lung transplantation.

Authors:  Marc Estenne; Marshall I Hertz
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

2.  Laparoscopic antireflux surgery in the lung transplant population.

Authors:  C L Lau; S M Palmer; D N Howell; R McMahon; D Hadjiliadis; J Gaca; T N Pappas; R D Davis; S Eubanks
Journal:  Surg Endosc       Date:  2002-07-29       Impact factor: 4.584

3.  Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient.

Authors:  Waleed Saleh; Andre Duranceau; Jocelyne Martin; Nicolas Noiseux; Charles Poirier; Pasquale Ferraro
Journal:  J Thorac Cardiovasc Surg       Date:  2008-09-14       Impact factor: 5.209

Review 4.  Classification of oesophageal motility abnormalities.

Authors:  S J Spechler; D O Castell
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

5.  Gastroparesis after combined heart and lung transplantation.

Authors:  Sudeep S Sodhi; Jin-Ping Guo; Alan H Maurer; Gerald O'Brien; Radhika Srinivasan; Henry P Parkman
Journal:  J Clin Gastroenterol       Date:  2002-01       Impact factor: 3.062

6.  Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease.

Authors:  G M Campos; S R DeMeester; J H Peters; S Oberg; P F Crookes; J A Hagen; C G Bremner; L F Sillin; R J Mason; T R DeMeester
Journal:  Arch Surg       Date:  2001-11

7.  Gastroesophageal reflux disease in lung transplant recipients.

Authors:  Denis Hadjiliadis; R Duane Davis; Mark P Steele; Robert H Messier; Christine L Lau; Steve S Eubanks; Scott M Palmer
Journal:  Clin Transplant       Date:  2003-08       Impact factor: 2.863

8.  Lung transplantation exacerbates gastroesophageal reflux disease.

Authors:  Lisa R Young; Denis Hadjiliadis; R Duane Davis; Scott M Palmer
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

9.  Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers.

Authors:  Radu Tutuian; Marcelo F Vela; Nagammapudur S Balaji; James L Wise; Joseph A Murray; Jeffrey H Peters; Steven S Shay; Donald O Castell
Journal:  Clin Gastroenterol Hepatol       Date:  2003-05       Impact factor: 11.382

Review 10.  Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do.

Authors:  Christopher G Streets; Tom R DeMeester
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

View more
  18 in total

1.  The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation.

Authors:  P Marco Fisichella; Christopher S Davis; Peter W Lundberg; Erin Lowery; Ellen L Burnham; Charles G Alex; Luis Ramirez; Karen Pelletiere; Robert B Love; Paul C Kuo; Elizabeth J Kovacs
Journal:  Surgery       Date:  2011-10       Impact factor: 3.982

2.  The prevalence and extent of gastroesophageal reflux disease correlates to the type of lung transplantation.

Authors:  Piero Marco Fisichella; Christopher S Davis; Vidya Shankaran; James Gagermeier; Daniel Dilling; Charles G Alex; Elizabeth J Kovacs; Raymond J Joehl; Robert B Love
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2012-02       Impact factor: 1.719

3.  Pulmonary immune changes early after laparoscopic antireflux surgery in lung transplant patients with gastroesophageal reflux disease.

Authors:  P Marco Fisichella; Christopher S Davis; Erin Lowery; Matthew Pittman; James Gagermeier; Robert B Love; Elizabeth J Kovacs
Journal:  J Surg Res       Date:  2012-04-18       Impact factor: 2.192

4.  Laparoscopic antireflux surgery for gastroesophageal reflux disease after lung transplantation.

Authors:  P Marco Fisichella; Christopher S Davis; James Gagermeier; Daniel Dilling; Charles G Alex; Jennifer A Dorfmeister; Elizabeth J Kovacs; Robert B Love; Richard L Gamelli
Journal:  J Surg Res       Date:  2011-06-22       Impact factor: 2.192

5.  The diagnostic value of gastroesophageal reflux disease (GERD) symptoms and detection of pepsin and bile acids in bronchoalveolar lavage fluid and exhaled breath condensate for identifying lung transplantation patients with GERD-induced aspiration.

Authors:  Nicholas P Reder; Christopher S Davis; Elizabeth J Kovacs; P Marco Fisichella
Journal:  Surg Endosc       Date:  2014-01-11       Impact factor: 4.584

6.  Aspiration, localized pulmonary inflammation, and predictors of early-onset bronchiolitis obliterans syndrome after lung transplantation.

Authors:  P Marco Fisichella; Christopher S Davis; Erin Lowery; Luis Ramirez; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Am Coll Surg       Date:  2013-04-28       Impact factor: 6.113

Review 7.  Evaluation of Gastroesophageal Reflux Disease.

Authors:  P Marco Fisichella; Ciro Andolfi; George Orthopoulos
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

8.  Both Pre-Transplant and Early Post-Transplant Antireflux Surgery Prevent Development of Early Allograft Injury After Lung Transplantation.

Authors:  Wai-Kit Lo; Hilary J Goldberg; Jon Wee; P Marco Fisichella; Walter W Chan
Journal:  J Gastrointest Surg       Date:  2016-01       Impact factor: 3.452

9.  Usefulness of pH monitoring in predicting the survival status of patients with scleroderma awaiting lung transplantation.

Authors:  Piero Marco Fisichella; Nicholas P Reder; James Gagermeier; Elizabeth J Kovacs
Journal:  J Surg Res       Date:  2014-03-15       Impact factor: 2.192

10.  Long term complications following 54 consecutive lung transplants.

Authors:  Walther Tabarelli; Hugo Bonatti; Dominique Tabarelli; Miriam Eller; Ludwig Müller; Elfriede Ruttmann; Cornelia Lass-Flörl; Clara Larcher; Christian Geltner
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.